Hyperpolarized Xe129
Phase 1Small molecule
Hyperpolarized Xe129 is one of 83 small molecule programs targeting Pulmonary Arterial Hypertension. It is currently in Phase 1.
4
Indications
10
Total Trials
8
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
309 competitors in COVID-19
#DrugCompanyPhaseTrials
1Hyperpolarized Xe129
UUniversity of Kansas Medical Center
Phase 1
Glucocorticoid
AbbViePreclinical
Statins
SanofiPreclinical
Rayaldee
OOrganon and Co
Preclinical
SARS-COV-2 VACCINE
ModernaPreclinical
Biological Collection
AAssistance Publique - Hôpitaux de Paris
Preclinical
Piperacillin/tazobactam
PfizerPreclinical
Aprotinin
BayerPreclinical
Sivelestat Sodium
TThe First Hospital of Jilin University
Preclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pulmonary Arterial Hypertension1 trial
Lung Disease1 trial
Regional Monitoring of CF Lung Disease
Recruiting·—·Phase 1·NCT06339593·60 enrolled
CAR1 trial
5 more indications
Pulmonary Disease1 trial
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Recruiting·—·Phase 1·NCT04624490·260 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hyperpolarized Xe129. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details